BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Virginia Tech//VT Calendar//EN
BEGIN:VEVENT
DTSTAMP:20120913T202000Z
UID:1345560761737@events.msu.edu
CATEGORIES:Conferences / Seminars / Lectures
DTSTART:20120913T202000Z
DTEND:20120914T035900Z
SUMMARY:MAX T. ROGERS DISTINGUISHED LECTURESHIP IN CHEMISTRY
DESCRIPTION:
 The MAX T. ROGERS DISTINGUISHED LECTURESHIP welcomes 
 a lecture by Professor Raymond Charles 
 Stevens, Departments of Molecular Biology and 
 Chemistry, The Scripps Research Institute, 
 La Jolla, CA\n
 \n
 Adventures in High Throughput 
 Structure Based Drug Discovery\n
 \n
 Abstract\n
 \n
 During the past 10 years significant progress 
 has been made in developing novel high throughput 
 structural biology technologies for protein 
 cloning, expression, purification, crystallization, 
 crystal imaging, synchrotron beamline 
 data collection, NMR analysis, and structure 
 determination/analysis. These developments 
 are largely a result of the U.S. NIGMS Protein 
 Structure Initiative, and efforts in Europe 
 (e.g. SPINE) and Japan (e.g. Protein-3000). 
  At The Scripps Research Institute, we have 
 been able to miniaturize, automate and parallelize 
 the structural biology processes using 
 nanoliter volume technologies and more recently 
 with human membrane proteins using lipidic 
 cubic phase and pre-crystallization tools. 
 The majority of these developments have now 
 been commercialized and are being used by both 
 traditional structural biology labs and structural 
 genomics centers.  Accordingly, significantly 
 smaller amounts of materials can be 
 used at all steps, and more parallel experiments 
 can be engineered (genetically and mechanically) 
 within the same space and time constraints, 
 at lower costs.   Application and results 
 from these efforts towards entire proteomes 
 (e.g. T. maritima, SARS), enzyme pathways/families 
 (e.g. catecholamine biosynthesis, 
 botulinum neurotoxins), high value drug targets 
 (e.g. DPPIV, PAL) including G-protein Coupled 
 Receptors (GPCRs) are now starting to emerge 
 and will be presented.  From these efforts, 
 multiple biotechnology companies have emerged 
 and generated marketed drugs or compounds 
 now in the clinic to treat a number of human 
 diseases (e.g. Syrrx, MemRx, Receptos, RuiYi). 
  Lastly, lessons that we have learned from 
 the past 10 years leads us to conclude that 
 integration of the new individual technologies 
 will significantly increase the levels of structure 
 determination successes and throughput 
 than is currently possible today.\n\n
 Price: free\n
 Sponsor: Chemistry\n
 Sponsor's Homepage: http://www.chemistry.msu.edu/\n
 Contact name: Rebecca Townsend\n
 Contact phone: 517.355.9175 x345\n
 Contact email: townsend@chemistry.msu.edu\n
LOCATION:136 Chemistry Building
END:VEVENT
END:VCALENDAR